Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies
Open Access
- 28 December 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (12) , e0208147
Abstract
Canine diffuse large B-cell lymphoma (DLBCL) is one of the most common cancers in dogs which shares remarkable similarities with its human counterpart, making the dog an excellent model for the investigation of novel therapeutic agents. However, the integration of canine lymphoma in comparative studies has been limited due in part to the lack of suitable xenograft mouse models for preclinical studies. To overcome these limitations, we established and characterized a localized subcutaneous bioluminescent canine DLBCL xenograft mouse model. The canine CLBL-1 cell line stably expressing the luciferase and green fluorescent protein reporters was generated and used to establish the xenograft tumor model. A pilot study was first conducted with three different cell densities (0.1×106, 0.5×106 and 1×106 cells) in SCID mice. All mice presented homogeneous tumor induction within eight days after subcutaneous injection, with a 100% engraftment efficiency and no significant differences were observed among groups. The tumors were highly aggressive and localized at the site of inoculation and reproduced histological features and immunophenotype consistent with canine DLBCL. Importantly, xenograft tumors were detected and quantified by bioluminescent imaging. To assess response to therapy, a therapeutic study with a histone deacetylase inhibitor, panobinostat, was performed. The results demonstrated that panobinostat (20 mg/kg) efficiently inhibited tumor growth and that bioluminescent imaging allowed the monitorization and quantification of tumor response to therapy. In summary, this study provides a bioluminescence canine DLBCL model that offers high engraftment efficiency, preservation of tumor features, and noninvasive monitoring of tumor progression, validating the model as a promising preclinical tool for both veterinary and human medicine.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (IF/01010/2013)
- Fundação para a Ciência e a Tecnologia (SFRH/BPD/100522/2014)
- Fundação para a Ciência e a Tecnologia (SFRH/BD/90514/2012)
- Fundação para a Ciência e a Tecnologia (SFRH/ BD/131468/2017)
This publication has 39 references indexed in Scilit:
- Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL)PLOS ONE, 2013
- Authentication of Primordial Characteristics of the CLBL-1 Cell Line Prove the Integrity of a Canine B-Cell Lymphoma in a Murine In Vivo ModelPLOS ONE, 2012
- The dog as a possible animal model for human non‐Hodgkin lymphoma: a reviewHematological Oncology, 2012
- A Tumor-Related Lymphoid Progenitor Population Supports Hierarchical Tumor Organization in Canine B-Cell LymphomaJournal of Veterinary Internal Medicine, 2011
- Predictors of long-term survival in dogs with high-grade multicentric lymphomaJournal of the American Veterinary Medical Association, 2011
- In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living AnimalsSensors, 2010
- Beyond chemotherapy: new agents for targeted treatment of lymphomaNature Reviews Clinical Oncology, 2010
- NOD/SCID mouse model of canine T‐cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imagingVeterinary and Comparative Oncology, 2008
- Establishment of human tumor xenografts in immunodeficient miceNature Protocols, 2007
- Establishment and Characterization of a New Canine B-Cell Leukemia Cell Line.Journal of Veterinary Medical Science, 1996